Why a 63% Vertex Selloff Didn’t Scare Off a New $13 Million Investor

After a brutal drawdown, Vertex is quietly doing the things long-term investors usually say they want and one fund just ...

Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress

Vertex Pharmaceuticals (VRTX) just checked several big boxes at once, with upbeat pediatric data for CASGEVY, fresh momentum in its kidney disease program, and a wave of investor interest following ...
The Boston Globe

Vertex’s CEO was an AI skeptic. But not anymore.

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
FiercePharma

Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
Investopedia

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
FiercePharma

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Seeking Alpha

Vertex Pharmaceuticals stock falls as pain drug fails in phase 2

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
The Boston Globe

Vertex next-generation pain candidate fails Phase 2 trial

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...
Bloomberg L.P.

Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...